Business Description
Thiogenesis Therapeutics Corp
NAICS : 325412
SIC : 3741
ISIN : CA88410L1022
Description
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -80.3 | |||||
3-Year EPS without NRI Growth Rate | -80.3 | |||||
3-Year FCF Growth Rate | -69.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.78 | |||||
9-Day RSI | 72.17 | |||||
14-Day RSI | 64.24 | |||||
6-1 Month Momentum % | -15.66 | |||||
12-1 Month Momentum % | 6.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.49 | |||||
Quick Ratio | 16.49 | |||||
Cash Ratio | 16.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.9 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -99.4 | |||||
ROA % | -88.27 | |||||
ROCE % | -102.4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.56 | |||||
Price-to-Tangible-Book | 6.17 | |||||
EV-to-EBIT | -5.8 | |||||
EV-to-Forward-EBIT | -3.74 | |||||
EV-to-EBITDA | -5.8 | |||||
EV-to-Forward-EBITDA | -3.74 | |||||
EV-to-FCF | -5.5 | |||||
Price-to-Net-Current-Asset-Value | 6.17 | |||||
Price-to-Net-Cash | 6.73 | |||||
Earnings Yield (Greenblatt) % | -17.23 | |||||
FCF Yield % | -12.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Thiogenesis Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -0.12 | ||
Beta | 0 | ||
Volatility % | 30.66 | ||
14-Day RSI | 64.24 | ||
14-Day ATR (C$) | 0.01864 | ||
20-Day SMA (C$) | 0.688 | ||
12-1 Month Momentum % | 6.06 | ||
52-Week Range (C$) | 0.6 - 1.06 | ||
Shares Outstanding (Mil) | 45.5 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Thiogenesis Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Thiogenesis Therapeutics Corp Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Thiogenesis Therapeutics Corp Frequently Asked Questions
What is Thiogenesis Therapeutics Corp(TSXV:TTI)'s stock price today?
The current price of TSXV:TTI is C$0.74. The 52 week high of TSXV:TTI is C$1.06 and 52 week low is C$0.60.
When is next earnings date of Thiogenesis Therapeutics Corp(TSXV:TTI)?
The next earnings date of Thiogenesis Therapeutics Corp(TSXV:TTI) is .
Does Thiogenesis Therapeutics Corp(TSXV:TTI) pay dividends? If so, how much?
Thiogenesis Therapeutics Corp(TSXV:TTI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |